Ocuphire will host a Virtual Investor R&D Day at which six ophthalmic Key Opinion Leaders (KOLs) from retina, optometry and refractive surgery practices will share their thoughts on three large unmet indications, RM, presbyopia, and DR/DME, addressed by Ocuphire’s two late-stage clinical drug assets, Nyxol and APX3330, and provide status updates on their development programs.